Currency In USD
| Previous Close | 22.86 |
| Open | 22.98 |
| Day High | 24.7 |
| Day Low | 22.21 |
| 52-Week High | 31.35 |
| 52-Week Low | 3.76 |
| Volume | 934,814 |
| Average Volume | 1.31M |
| Market Cap | 2.98B |
| PE | -6.17 |
| EPS | -3.92 |
| Moving Average 50 Days | 26.44 |
| Moving Average 200 Days | 21.55 |
| Change | 1.31 |
Alumis to Present at the Leerink Partners Global Healthcare Conference
GlobeNewswire Inc.
Mar 02, 2026 1:05 PM GMT
SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that Martin Babler,
Alumis to Participate in Upcoming February Investor Conferences
GlobeNewswire Inc.
Feb 05, 2026 1:05 PM GMT
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that the Company wil
Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
GlobeNewswire Inc.
Jan 09, 2026 9:05 PM GMT
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the clos